167 related articles for article (PubMed ID: 8625762)
21. Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins--identification of a T-kinin-releasing rat kallikrein.
El Moujahed A; Brillard-Bourdet M; Juliano MA; Moreau T; Chagas JR; Gutman N; Prado ES; Gauthier F
Eur J Biochem; 1997 Jul; 247(2):652-8. PubMed ID: 9266709
[TBL] [Abstract][Full Text] [Related]
22. Low-salt diet downregulates plasma but not tissue kallikrein-kinin system.
Hilgenfeldt U; Puschner T; Riester U; Finsterle J; Hilgenfeldt J; Ritz E
Am J Physiol; 1998 Jul; 275(1):F88-93. PubMed ID: 9689009
[TBL] [Abstract][Full Text] [Related]
23. [A role of kallikrein-kinin system in gut diseases].
Zelawski W; Witalińska-Labuzek J; Stadnicki A
Wiad Lek; 2005; 58(5-6):331-4. PubMed ID: 16238127
[TBL] [Abstract][Full Text] [Related]
24. Eicosanoid regulation of acute intestinal vascular permeability induced by intravenous peptidoglycan-polysaccharide polymers.
Woolverton CJ; White JJ; Sartor RB
Agents Actions; 1989 Mar; 26(3-4):301-9. PubMed ID: 2660498
[TBL] [Abstract][Full Text] [Related]
25. Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease.
Rahal K; Schmiedlin-Ren P; Adler J; Dhanani M; Sultani V; Rittershaus AC; Reingold L; Zhu J; McKenna BJ; Christman GM; Zimmermann EM
Inflamm Bowel Dis; 2012 Apr; 18(4):613-23. PubMed ID: 22431488
[TBL] [Abstract][Full Text] [Related]
26. Role of kallikrein-kinin system in the pathogenesis of bacterial cell wall-induced inflammation and enterocolitis.
DeLa Cadena RA; Sartor RB; Adam A; Raymond B; Legris F; Colman RW
Trans Assoc Am Physicians; 1992; 105():229-37. PubMed ID: 1309001
[No Abstract] [Full Text] [Related]
27. [Kallikrein-kinin system in acute empyema of pleura and pyopneumothorax].
Tseĭmakh EA; Kurasov VN
Khirurgiia (Mosk); 1999; (7):40-2. PubMed ID: 10459186
[TBL] [Abstract][Full Text] [Related]
28. Streptokinase-induced activation of the kallikrein-kinin system and of the contact phase in patients with acute myocardial infarction.
Hoffmeister HM; Ruf M; Wendel HP; Heller W; Seipel L
J Cardiovasc Pharmacol; 1998 May; 31(5):764-72. PubMed ID: 9593077
[TBL] [Abstract][Full Text] [Related]
29. Effect of Neurotropin on the activation of the plasma kallikrein-kinin system.
Nishikawa K; Reddigari SR; Silverberg M; Kuna PB; Yago H; Nagaki Y; Toyomaki Y; Suehiro S; Kaplan AP
Biochem Pharmacol; 1992 Mar; 43(6):1361-9. PubMed ID: 1562287
[TBL] [Abstract][Full Text] [Related]
30. Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Devani M; Vecchi M; Ferrero S; Avesani EC; Arizzi C; Chao L; Colman RW; Cugno M
Dig Liver Dis; 2005 Sep; 37(9):665-73. PubMed ID: 15949977
[TBL] [Abstract][Full Text] [Related]
31. Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis.
Sainz IM; Isordia-Salas I; Castaneda JL; Agelan A; Liu B; DeLa Cadena RA; Pixley RA; Adam A; Sartor RB; Colman RW
Arthritis Rheum; 2005 Aug; 52(8):2549-52. PubMed ID: 16059911
[TBL] [Abstract][Full Text] [Related]
32. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.
Wachtfogel YT; Hack CE; Nuijens JH; Kettner C; Reilly TM; Knabb RM; Bischoff R; Tschesche H; Wenzel H; Kucich U
Am J Physiol; 1995 Mar; 268(3 Pt 2):H1352-7. PubMed ID: 7535008
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of the plasma kallikrein-kinin system inhibitor, haemaphysalin, from hard tick, Haemaphysalis longicornis.
Kato N; Iwanaga S; Okayama T; Isawa H; Yuda M; Chinzei Y
Thromb Haemost; 2005 Feb; 93(2):359-67. PubMed ID: 15711755
[TBL] [Abstract][Full Text] [Related]
34. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Devani M; Cugno M; Vecchi M; Ferrero S; Di Berardino F; Avesani EC; de Franchis R; Colman RW
Am J Gastroenterol; 2002 Aug; 97(8):2026-32. PubMed ID: 12190172
[TBL] [Abstract][Full Text] [Related]
35. Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.
Fujimori Y; Nakamura T; Shimizu K; Yamamuro T; Wanaka K; Okamoto S; Katsuura Y
Agents Actions; 1993 May; 39(1-2):42-8. PubMed ID: 8285139
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease.
Adler J; Rahal K; Swanson SD; Schmiedlin-Ren P; Rittershaus AC; Reingold LJ; Brudi JS; Shealy D; Cai A; McKenna BJ; Zimmermann EM
Inflamm Bowel Dis; 2013; 19(4):683-90. PubMed ID: 23429466
[TBL] [Abstract][Full Text] [Related]
37. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats.
McCall RD; Haskill S; Zimmermann EM; Lund PK; Thompson RC; Sartor RB
Gastroenterology; 1994 Apr; 106(4):960-72. PubMed ID: 8144001
[TBL] [Abstract][Full Text] [Related]
38. Increased kallikrein activity in the rabbit renal vasculature during low sodium intake.
Kuo JJ; Zimmerman BG
Clin Exp Pharmacol Physiol; 1997 Feb; 24(2):153-6. PubMed ID: 9075588
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of rabbit corpus cavernosum relaxation mediated by the tissue kallikrein-kinin system.
Lopes-Martins RA; Antunes E; Oliva ML; Sampaio CA; Burton J; de Nucci G
Br J Pharmacol; 1994 Sep; 113(1):81-6. PubMed ID: 7529116
[TBL] [Abstract][Full Text] [Related]
40. The kallikrein-kinin system: current and future pharmacological targets.
Moreau ME; Garbacki N; Molinaro G; Brown NJ; Marceau F; Adam A
J Pharmacol Sci; 2005 Sep; 99(1):6-38. PubMed ID: 16177542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
